摘要
目的探讨EML4-ALK融合基因在非小细胞肺癌(NSCLC)中的表达及其与临床病理特征的关系。方法应用免疫组织化学SP法及组织芯片技术检测245例NSCLC及80例癌旁组织中EML4-ALK的表达情况,并分析其表达与NSCLC临床病理特征的关系。结果 EML4-ALK蛋白在NSCLC组织中的阳性表达率为7.35%(18/245),而在癌旁组织中无表达。EML4-ALK在NSCLC中的表达与性别、吸烟史、病理类型及临床分期密切相关(P<0.05)。结论 EML4-ALK可能在NSCLC的发生、发展过程中起到了重要作用,可作为潜在的治疗靶点。
Objective To investigate the expression of EML4-ALK in non-small cell lung cancer（NSCLC） and the correlation with clinical pathological features. Methods The expression of EMIA-ALK was detected in 245 cases of NSCLC and 80 cases of adjacent normal tissues using immunohistochemistry and tissue microarray technique. The correlation between the clinicopathological features and the expression of EMIA-ALK was analyzed. Results The positive rate of EML4-ALK in NSCLC was 7.35% （ 18/245 ） ,while it was 0（0/ 80）in adjacent normal tissues. EMIA-ALK expression was significantly correlated with gender, smoking history, histological type and clinical stage （P 〈 0. 05 ）. Conclusion EML4-ALK may play an important role in the occurrence and development of NSCLC. It may be- come a potential target of clinical therapy.
出处
《临床肿瘤学杂志》
CAS
2013年第8期688-690,共3页
Chinese Clinical Oncology
基金
湖北省自然科学基金资助项目(2011CDC038)
关键词
非小细胞肺癌
免疫组织化学
临床病理特征
Non-small cell lung cancer（NSCLC）
Immunohistochemistry
Clinicopathological features
